6-K 1 dp77722_6k.htm FORM 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16

OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June, 2017

 

Commission File Number: 001-37891

 

AC IMMUNE SA

(Exact name of registrant as specified in its charter)

 

EPFL Innovation Park

Building B

1015 Lausanne, Switzerland

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F

X 

   Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes   No

X 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes   No

X 

 

 
 

 

Annual Ordinary Shareholders’ Meeting Results

 

On June 28, 2017, AC Immune SA (“AC Immune”) held its annual Ordinary Shareholders’ Meeting. The presentation that was given at the Ordinary Shareholders’ Meeting is attached hereto as Exhibit 99.1. The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

 

Agenda Item 1: Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2016

 

AC Immune shareholders approved the Annual Report, the Annual Statutory Financial Statements and the Financial Statements under IFRS of AC Immune SA for the year 2016, and took note of the Reports of the Auditors.

 

Agenda Item 2: Appropriation of Loss

 

AC Immune shareholders approved the addition of the net loss for the year 2016 in the amount of KCHF 7,628 to the loss brought forward of KCHF 24,930, resulting in a reduced new balance of loss brought forward of KCHF 32,558.

 

Agenda Item 3: Discharge of the Members of the Board of Directors and the Executive Committee

 

AC Immune shareholders approved the discharge the Board and the Executive Committee of their liabilities for their activities in the financial year 2016.

 

Agenda Item 4: Compensation for the Members of the Board of Directors and the Executive Committee

 

AC Immune shareholders approved:

 

A.The total maximum amount of non-performance-related compensation for the members of the Board of Directors covering the period from 1 July 2017 to 30 June 2018, i.e., CHF 428,000 (cash base compensation plus social security costs);

 

B.The maximum grant of equity or equity linked instruments for the members of the Board of Directors from 1 July 2017 to 30 June 2018 with maximum value of CHF 451,000 (equity or equity linked instruments value plus social security costs);

 

C.The total maximum amount of non-performance-related cash compensation for the members of the Executive Committee from 1 July 2017 to 30 June 2018, i.e., CHF 1,554,000 (cash base compensation plus social security costs);

 

 
 
D.The total maximum amount of variable compensation for the members of the Executive Committee for the current year 2017, i.e., CHF 782,000 (cash compensation plus social security costs); and

 

E.The maximum grant of equity or equity linked instruments for the members of the Executive Committee from 1 July 2017 to 30 June 2018 with maximum value of CHF 3,472,000 (equity or equity linked instruments value plus social security costs).

 

Agenda Item 5: Election of the Members of the Board

 

AC Immune shareholders approved the re-election of Martin Velasco as member and as Chairman of the Board, Peter Bollmann, Friedrich von Bohlen, Andrea Pfeifer, Detlev Riesner and Thomas Graney as members of the Board of Directors, each until the end of the next Ordinary General Meeting.

 

Agenda Item 6: Election to the Compensation, Nomination & Corporate Governance Committee

 

AC Immune shareholders approved the re-election of Detlev Riesner, Martin Velasco and Tom Graney as members of the Compensation, Nomination & Corporate Governance Committee, each until the end of the next Ordinary General Meeting.

 

Agenda Item 7: Re-Election of the independent proxy

 

AC Immune shareholders approved the re-election of Bugnion Ballansat Ehrler, represented by Gérald Virieux, as AC Immune’s independent proxy until the end of the next Ordinary General Meeting.

 

Agenda Item 8: Re-Election of the Auditors

 

AC Immune shareholders approved the re-election of Ernst & Young SA, in Lancy, for a term of office of one year.

 

 
 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    AC IMMUNE SA
     
      By: /s/ Andrea Pfeifer
        Name: Andrea Pfeifer
        Title: Chief Executive Officer

  

      By: /s/ Joerg Hornstein
        Name: Joerg Hornstein
        Title: Chief Financial Officer

Date: June 28, 2017

 

 
 

EXHIBIT INDEX

 

Exhibit Number Description
99.1 Annual Ordinary Shareholders’ Meeting presentation